Related Experiment Video

Updated: Dec 30, 2025

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs
07:39

SA-β-Galactosidase-Based Screening Assay for the Identification of Senotherapeutic Drugs

Published on: June 28, 2019

24.9K

Cardiac Glycosides as Senolytic Compounds

Nadine Martin1, Olivier Soriani2, David Bernard1

  • 1Centre de Recherche en Cancérologie de Lyon, Institut National de la Santé et de la Recherche Médicale (INSERM) Unité 1052, Centre National de la Recherche Scientifique (CNRS) Unité Mixte de Recherche 5286, Université de Lyon, Centre Léon Bérard, Lyon, France.

Trends in Molecular Medicine
|January 28, 2020
PubMed

Insights

Senolytics eliminate harmful senescent cells, offering therapeutic potential for cancer and aging. Cardiac glycosides show promise as senolytic agents, effectively clearing these cells in recent studies.

Area of Science:

  • Gerontology
  • Pharmacology
  • Oncology

Background:

  • Senescent cells accumulate with age and disease, contributing to various pathologies.
  • Senolytics, compounds that clear senescent cells, are a promising therapeutic strategy.
  • Cardiac glycosides (CGs) are being investigated for their potential senolytic activity.

Purpose of the Study:

  • To identify and characterize senolytic compounds.
  • To evaluate the efficacy of cardiac glycosides as senolytics.
  • To explore the therapeutic applications of CGs in aging and cancer.

Main Methods:

  • Review of recent literature on senolytics and cardiac glycosides.
  • Analysis of studies reporting senolytic activity of CGs.
  • Assessment of CG efficacy in relevant pathophysiological models.

Main Results:

  • Two recent studies demonstrate the senolytic activity of cardiac glycosides.
  • Cardiac glycosides show efficacy in clearing senescent cells.
  • These findings highlight CGs' therapeutic potential.

Conclusions:

  • Cardiac glycosides represent a promising class of senolytic agents.
  • Further research into CGs could lead to novel treatments for aging and cancer.
  • Targeting senescent cells with CGs offers a new therapeutic avenue.
Keywords:
agingcancercardiac glycosidescellular senescencesenolytics

More Related Videos

A Simple and Effective Method to Consistently Isolate Mouse Cardiomyocytes06:25

A Simple and Effective Method to Consistently Isolate Mouse Cardiomyocytes

Published on: November 11, 2022

3.7K
Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

2.0K

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
842
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.3K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
166
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
253